A Phase 1/2 Trial of a Tetravalent Live-Attenuated Dengue Vaccine in Flavivirus-Native Thai Infants
Watanaveeradej, David W. Vaughn(Armed Forces Research Institute of Medical Science), Supamit Chunsuttiwat(Ministry of Public Health), M. P. Mammen, S Hengprasert, Sriluck Simasathien(Walter Reed Army Institute of Research), Stephen J. Thomas(Global Viral), Kenneth H. Eckels(Walter Reed Army Institute of Research), Angkool Kerdpanich(Walter Reed Army Institute of Research), Bruce L. Innis(Universidad de Los Andes, Chile), Chanchai Aree, Robert Putnak, Robert V. Gibbons, Ananda Nisalak(Armed Forces Research Institute of Medical Science), Timothy P. Endy(Walter Reed Army Institute of Research), R Samakoses, Wellington Sun, Yanee Hutagalung, R J Jarman, K Tanakijaru
Unknown
November 1, 2006
Cited by 0
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
|New England Journal of Medicine|2009|3k
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
|New England Journal of Medicine|2021|937
Neurological manifestations of dengue infection
|The Lancet|2000|637
Rapid development of a DNA vaccine for Zika virus
|Science|2016|402